Zegerid - FDA to begin review of chewable heartburn drug
‘The FDA has accepted for review a new drug application from Santarus Inc, for a chewable form of the company’s heartburn and reflux disease medicine, Zegerid.
Santarus, a pharmaceutical company focused on therapies for gastrointestinal diseases and disorders, expects the FDA will complete its review or give some response by March 26, 2006.
If the application is approved for marketing, the tablets will be the first immediate-release proton pump inhibitor (PPI) in a chewable tablet formulation for the treatment of heartburn and other symptoms associated with gastro-esophageal reflux disease (GERD), erosive esophagitis, duodenal ulcers and gastric ulcers.’
Read more at FDA to begin review of chewable heartburn drug
Recent Entries
- Sigma Pharmaceuticals year profit rises 27 pct
- South African citizens cheap drug guinea pigs
- Two drugs test victims face a year in coma
- Can drug companies improve their reputation?
- Pfizer Sees 40 Percent Rise in 2006 Net on Cost Cuts
- Pfizer’s Forecast Disappoints
- Pharmaceutical RFID Adoption Stalls
- Inhalable Drug Might Bring Sigh Of Relief To Diabetes Patients
- GlaxoSmithKline unveils best results since merger
- Pfizer Sues Teva, Sandoz Over Zithromax